Safety and Immunogenicity of a New Trivalent Inactivated Split-virus Influenza Vaccine in Healthy Korean Children: A Randomized, Double-blinded, Active-controlled, Phase III Study

We report results of a randomized, double-blinded, active-controlled, phase III study conducted to evaluate the immunogenicity and safety of a new trivalent inactivated split-virus influenza vaccine (GC501) manufactured by the Green Cross Corporation in Korea. A total of 283 healthy children aged 6...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Jin-Han, Oh, Chi-Eun, Lee, Jina, Lee, Soo-Young, Cha, Sung-Ho, Kim, Dong Soo, Kim, Hyun-Hee, Lee, Jung-Hyun, Kim, Jin-Tack, Ma, Sang-Hyuk, Hong, Young-Jin, Cheong, Hee Jin, Lee, Hoan-Jong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3207044/
https://www.ncbi.nlm.nih.gov/pubmed/22065897
http://dx.doi.org/10.3346/jkms.2011.26.11.1421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3207044/
https://www.ncbi.nlm.nih.gov/pubmed/22065897
http://dx.doi.org/10.3346/jkms.2011.26.11.1421

Ejemplares similares